View Future GrowthIMV 過去の業績過去 基準チェック /06IMVの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2022最近の業績更新Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.すべての更新を表示Recent updatesお知らせ • Sep 23IMV Inc. Files Form 15IMV Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.お知らせ • Jul 08Nasdaq to Delist the Common Shares of IMVNasdaq announced on July 06, 2023 that it will delist the common shares of IMV Inc. The company’s securities were suspended on May 11, 2023, and have not traded on Nasdaq since that time.お知らせ • May 12IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite IndexIMV Inc. has been added to NASDAQ Composite Index (^COMP).お知らせ • May 09IMV Receives Nasdaq Delisting NoticeIMV Inc. (the “Company” or “IMV”) announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”). The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).お知らせ • Feb 14IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize TrialIMV Inc. announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL"). Overall Response Rate ("ORR") will be communicated when the totality of stage one data are available for definitive assessment.Board Change • Jan 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Saman Maleki was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 09IMV Inc. Announces Board ChangesIMV Inc. announced the appointment of Shabnam Kazmi to the Board of Directors. Ms. Kazmi is an experienced CEO and Founder with over 30 years experience in top-tier global biopharma companies such as Bristol-Myers Squibb, Sanofi and Otsuka America Pharmaceuticals. She has deep expertise in oncology, having launched and managed multiple top tier products across both solid tumors and hematology. She currently serves as the CEO of Asellus Ventures, a healthcare advisory and investment firm. She has led multiple global joint ventures and successfully managed large complex projects across 75 countries with a focus on managing risk and creating asset value. Ms. Kazmi has consistently achieved outstanding financial results and growth in value for shareholders by managing $1B+ P&Ls, developing innovative strategies, M&A, building highly talented teams, raising capital, and successfully launching and commercializing oncology products for the treatment of both solid tumors and hematology. Her passion for patients and over 20 years of board service has led to multiple awards from cancer patient groups, and she currently serves as a Board Member of the Prevent Cancer Foundation. Ms. Kazmi has a Bachelor’s degree in Economics and Biochemistry from Smith College and an MBA from Harvard Business School. Ms. Kazmi’s appointment follows the decision of Ms. Julia P. Gregory who has served on IMV's Board of Directors since June 2018, to retire from the Board of Directors.Seeking Alpha • Sep 15IMV to cut ~33% workforce amid reorganizationIMV (NASDAQ:IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV intends to focus its resources on ongoing MVP-S clinical programs in immuno-oncology (IO), notably phase 2b trials VITALIZE in relapsed/ refractory Diffuse Large B Cell Lymphoma (DLBCL) and AVALON for advanced metastatic ovarian cancer. In addition, the Canadian company said that Saman Maleki was appointed to the board replacing Brittany Davison who will be promoted to chief accounting officer from her current role as senior vice president, Finance. Maleki is an Assistant Professor of Oncology, Pathology & Laboratory Medicine, and Medical Biophysics at Western University and is an expert in the field of immuno-oncology, according to IMV. IMV +4.05% to $0.77 premarket Sept. 15Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Jul 08IMV receives Nasdaq non-compliance letterIMV (NASDAQ:IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance.Board Change • Jul 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Executive Departure • Aug 05CEO & Director Frederic Ors has left the companyDuring their tenure, earnings grew by 32% annually compared to the industry average of 23%. On the 1st of August, Frederic Ors left the company after 5.3 in the role. As of March 2021, Frederic still personally held 301.47k shares (US$1.0m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Frederic's leadership, the company delivered a total shareholder return of 21%.Board Change • Jul 31High number of new directorsIndependent Director Kyle Kuvalanka was the last director to join the board, commencing their role in 2021.Recent Insider Transactions • Jul 25CEO & Director recently bought US$147k worth of stockOn the 23rd of July, Frederic Ors bought around 100k shares on-market at roughly US$1.47 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of US$195k worth in shares.Executive Departure • Jun 15Chief Medical Officer Joanne Schindler has left the companyOn the 11th of June, Joanne Schindler's tenure as Chief Medical Officer ended after 1.6 years in the role. We don't have any record of a personal shareholding under Joanne's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Apr 07Independent Director has left the companyOn the 1st of April, Wayne Pisano's tenure as Independent Director ended after 9.5 years in the role. As of December 2020, Wayne personally held 77.28k shares (US$238k worth at the time). Wayne is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 05New 90-day high: US$4.36The company is up 18% from its price of US$3.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$16.30 per share.Is New 90 Day High Low • Dec 19New 90-day low: US$3.13The company is down 37% from its price of US$4.97 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$13.97 per share.Analyst Estimate Surprise Post Earnings • Nov 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates by 12%.Is New 90 Day High Low • Oct 27New 90-day low: US$3.15The company is down 36% from its price of US$4.95 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.95 per share.Is New 90 Day High Low • Oct 12New 90-day low: US$3.85The company is down 17% from its price of US$4.63 on 14 July 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.25 per share.収支内訳IMV の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:IMVI.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 220-3817030 Sep 220-4117030 Jun 220-4318031 Mar 220-4017031 Dec 210-3716030 Sep 210-3215030 Jun 210-2813031 Mar 210-2612031 Dec 200-2611030 Sep 200-2510030 Jun 200-249031 Mar 200-228031 Dec 190-218030 Sep 190-207030 Jun 190-197031 Mar 190-197031 Dec 180-167030 Sep 180-157030 Jun 180-126031 Mar 180-105031 Dec 170-105030 Sep 170-94030 Jun 170-84-131 Mar 170-73-131 Dec 160-73030 Sep 160-63130 Jun 160-63331 Mar 160-73431 Dec 150-63330 Sep 150-633質の高い収益: IMVI.Fが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: IMVI.Fの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: IMVI.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: IMVI.Fの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: IMVI.Fの過去 1 年間の収益成長がBiotechs業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: IMVI.Fは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 15:14終値2026/05/22 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IMV Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Sarah ChiassonBeacon Securities LimitedMayank MamtaniB. Riley Securities, Inc.Thomas ShraderBTIG5 その他のアナリストを表示
Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 23IMV Inc. Files Form 15IMV Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.
お知らせ • Jul 08Nasdaq to Delist the Common Shares of IMVNasdaq announced on July 06, 2023 that it will delist the common shares of IMV Inc. The company’s securities were suspended on May 11, 2023, and have not traded on Nasdaq since that time.
お知らせ • May 12IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite IndexIMV Inc. has been added to NASDAQ Composite Index (^COMP).
お知らせ • May 09IMV Receives Nasdaq Delisting NoticeIMV Inc. (the “Company” or “IMV”) announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”). The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).
お知らせ • Feb 14IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize TrialIMV Inc. announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL"). Overall Response Rate ("ORR") will be communicated when the totality of stage one data are available for definitive assessment.
Board Change • Jan 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Saman Maleki was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 09IMV Inc. Announces Board ChangesIMV Inc. announced the appointment of Shabnam Kazmi to the Board of Directors. Ms. Kazmi is an experienced CEO and Founder with over 30 years experience in top-tier global biopharma companies such as Bristol-Myers Squibb, Sanofi and Otsuka America Pharmaceuticals. She has deep expertise in oncology, having launched and managed multiple top tier products across both solid tumors and hematology. She currently serves as the CEO of Asellus Ventures, a healthcare advisory and investment firm. She has led multiple global joint ventures and successfully managed large complex projects across 75 countries with a focus on managing risk and creating asset value. Ms. Kazmi has consistently achieved outstanding financial results and growth in value for shareholders by managing $1B+ P&Ls, developing innovative strategies, M&A, building highly talented teams, raising capital, and successfully launching and commercializing oncology products for the treatment of both solid tumors and hematology. Her passion for patients and over 20 years of board service has led to multiple awards from cancer patient groups, and she currently serves as a Board Member of the Prevent Cancer Foundation. Ms. Kazmi has a Bachelor’s degree in Economics and Biochemistry from Smith College and an MBA from Harvard Business School. Ms. Kazmi’s appointment follows the decision of Ms. Julia P. Gregory who has served on IMV's Board of Directors since June 2018, to retire from the Board of Directors.
Seeking Alpha • Sep 15IMV to cut ~33% workforce amid reorganizationIMV (NASDAQ:IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV intends to focus its resources on ongoing MVP-S clinical programs in immuno-oncology (IO), notably phase 2b trials VITALIZE in relapsed/ refractory Diffuse Large B Cell Lymphoma (DLBCL) and AVALON for advanced metastatic ovarian cancer. In addition, the Canadian company said that Saman Maleki was appointed to the board replacing Brittany Davison who will be promoted to chief accounting officer from her current role as senior vice president, Finance. Maleki is an Assistant Professor of Oncology, Pathology & Laboratory Medicine, and Medical Biophysics at Western University and is an expert in the field of immuno-oncology, according to IMV. IMV +4.05% to $0.77 premarket Sept. 15
Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Jul 08IMV receives Nasdaq non-compliance letterIMV (NASDAQ:IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance.
Board Change • Jul 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Executive Departure • Aug 05CEO & Director Frederic Ors has left the companyDuring their tenure, earnings grew by 32% annually compared to the industry average of 23%. On the 1st of August, Frederic Ors left the company after 5.3 in the role. As of March 2021, Frederic still personally held 301.47k shares (US$1.0m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Frederic's leadership, the company delivered a total shareholder return of 21%.
Board Change • Jul 31High number of new directorsIndependent Director Kyle Kuvalanka was the last director to join the board, commencing their role in 2021.
Recent Insider Transactions • Jul 25CEO & Director recently bought US$147k worth of stockOn the 23rd of July, Frederic Ors bought around 100k shares on-market at roughly US$1.47 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of US$195k worth in shares.
Executive Departure • Jun 15Chief Medical Officer Joanne Schindler has left the companyOn the 11th of June, Joanne Schindler's tenure as Chief Medical Officer ended after 1.6 years in the role. We don't have any record of a personal shareholding under Joanne's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Apr 07Independent Director has left the companyOn the 1st of April, Wayne Pisano's tenure as Independent Director ended after 9.5 years in the role. As of December 2020, Wayne personally held 77.28k shares (US$238k worth at the time). Wayne is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 05New 90-day high: US$4.36The company is up 18% from its price of US$3.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$16.30 per share.
Is New 90 Day High Low • Dec 19New 90-day low: US$3.13The company is down 37% from its price of US$4.97 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$13.97 per share.
Analyst Estimate Surprise Post Earnings • Nov 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates by 12%.
Is New 90 Day High Low • Oct 27New 90-day low: US$3.15The company is down 36% from its price of US$4.95 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.95 per share.
Is New 90 Day High Low • Oct 12New 90-day low: US$3.85The company is down 17% from its price of US$4.63 on 14 July 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.25 per share.